WHO Chemical Risk Assessment Workshop on new and emerging risks to human health from chemicals RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Kick off European Project VITAL: Vaccines and InfecTious diseases in the Ageing popuLation Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.
Publication WHO Good Practice Brief RIVM Centre for Healthy Living The Good Practice Brief 'Centre for Healthy Living in the Netherlands: Building sustainable capacity and alliances for effective health promotion' has been published on the World Health Organ
Fewer TB patients in the Netherlands The key figures of the National Institute for Public Health and the Environment (RIVM) show that in 2017, the number of TB patients in the Netherlands fell below 800 TB patients for the first time
Hormone-disrupting effect methyl-, ethyl- and propylparaben still unclear RIVM has conducted literature research into the hormone-disrupting effects of the three most commonly used parabens (methyl-, ethyl- and propylparaben) and the exposure of consumers to these substa
Legislation on maximum permitted amount of synephrine in food supplements is desirable Harmful health effects of dietary supplements with high levels of synephrine, which are used to lose weight or improve sports performance, cannot be excluded.
RIVM develops a framework for a broader view of establishing food safety standards In Europe, strict requirements apply to food safety. Food safety standards are determined at international level.
Less meat and more tap water benefits health and the environment In the Netherlands, diets with a high environmental impact contain more meat and energy.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.